Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies

Oncoimmunology. 2022 Mar 23;11(1):2054106. doi: 10.1080/2162402X.2022.2054106. eCollection 2022.

Abstract

Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The antitumor efficacy of bispecific anti-CD19 × anti-CD3 (CD19×CD3) T cell engager (BiTE)-secreting STAb-T cells has been demonstrated in several mouse models of B-cell acute leukemia. Here, we have investigated the spatial topology and downstream signaling of the artificial immunological synapses (IS) that are formed by CAR-T or STAb-T cells. Upon interaction with CD19-positive target cells, STAb-T cells form IS with structure and signal transduction, which more closely resemble those of physiological cognate IS, compared to IS formed by CAR-T cells expressing a second-generation CAR bearing the same CD19-single-chain variable fragment. Importantly, while CD3 is maintained at detectable levels on the surface of STAb-T cells, indicating sustained activation mediated by the secreted BiTE, the anti-CD19 CAR was rapidly downmodulated, which correlated with a more transient downstream signaling. Furthermore, CAR-T cells, but not STAb-T cells, provoke an acute loss of CD19 in target cells. Such differences might represent advantages of the STAb-T strategy over the CAR-T approach and should be carefully considered in order to develop more effective and safer treatments for hematological malignancies.

Keywords: BiTE; CAR; CD19+ B cell malignancies; STAb; T cell-redirecting strategies; leukemia relapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD19 / metabolism
  • Hematologic Neoplasms* / metabolism
  • Hematologic Neoplasms* / pathology
  • Mice
  • Receptors, Chimeric Antigen*
  • Synapses / metabolism
  • T-Lymphocytes

Substances

  • Antigens, CD19
  • Receptors, Chimeric Antigen

Grants and funding

This work was supported by the Spanish Ministry of Science and Innovation (PID2020115444GB-I00 and RTC-2017-5944-1 to PR-N; and SAF2017-89437-P, PID2020-117323RB-I00, and PDC2021-121711-I00 to LA-V), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII, PI20/01030 to BB; and DTS20/00089 to LA-V), partially supported by the ERDF; the Spanish Association Against Cancer (AECC 19084 to LA-V; INNOV211832BLAN toB.B); and the CRIS Cancer Foundation (FCRIS-IFI-2018 and FCRIS-2021-0090 to LA-V). ISCIII-RICORS is supported within the Next Generation EU program (Plan de Recuperacion, Transformacion y Resiliencia). LD-A was supported by a Rio Hortega fellowship from the ISCIII (CM20/00004). OA-S was supported by a PhD fellowship from the Complutense University of Madrid. CD-A was supported by a predoctoral fellowship from the Spanish Ministry of Science and Innovation (PRE2018-083445).